Amgen Eyes Simultaneous Filing in Japan, US, EU for 3 Key Drivers, including Next-Gen BiTE Drug: R&D Chief

David Reese, Executive Vice President, Research and Development, Amgen Amgen is aiming for simultaneous regulatory filings in the US, Japan, and Europe for three mid- to late-stage assets that would drive the company’s growth over the coming years, including its...read more